# Spain Montelukast API Market

> Spain Montelukast API Market Research Report: Size, Share, Trend Analysis By Applications (Asthma, Allergic Rhinitis, Bronchospasm, Urticaria, Others) - Growth Outlook & Industry Forecast 2025 To 2035

- **Forecast Period:** 2025 - 2035
- **CAGR:** 9.54%
- **2024:** $ 20.2 Million
- **2025:** $ 22.13 Million
- **2035:** $ 55.04 Million
- **Key Players:** Merck & Co (US), Teva Pharmaceutical Industries (IL), Mylan N.V. (US), Sandoz (CH), Aurobindo Pharma (IN), Cipla (IN), Hikma Pharmaceuticals (GB), Zydus Cadila (IN)

**Report ID:** MRFR/HC/51338-HCR · **Pages:** 200 · **Author:** Rahul Gotadki & Garvit Vyas · **Last Updated:** February 06, 2026

**URL:** https://www.marketresearchfuture.com/reports/spain-montelukast-api-market-53099

---

## Market Summary

## **Spain Montelukast API Market Overview**

As per MRFR analysis, the Spain Montelukast API Market Size was estimated at 18 (USD Million) in 2023. The Spain Montelukast API Market Industry is expected to grow from 20.2 (USD Million) in 2024 to 65 (USD Million) by 2035. The Spain Montelukast API Market CAGR (growth rate) is expected to be around 11.21% during the forecast period (2025 - 2035).

### **Key Spain Montelukast API Market Trends Highlighted**

A variety of factors in the Spain Montelukast API market are driving several notable trends. Montelukast is in high demand as a therapeutic solution due to the increasing prevalence of respiratory diseases, particularly asthma and allergic rhinitis. The necessity for effective therapies is further emphasized by the Spanish government's initiatives to enhance healthcare access and medication availability.

Additionally, Spain has made substantial investments in healthcare research and development, which have resulted in improved drug formulations and innovative delivery methods for Montelukast. These developments have subsequently fueled market growth. The Spanish market is primed for opportunities, particularly with the increasing demand for generic formulations as the patents for Montelukast begin to expire.

By developing cost-effective versions of the drug, local manufacturers can expand accessibility for patients from a variety of socio-economic backgrounds and acquire a significant portion of the market. Additionally, the growing emphasis on preventive healthcare in Spain presents opportunities for the use of Montelukast in the management of conditions associated with chronic obstructive pulmonary disease (COPD) and allergies.

Market trends have recently suggested that there is a growing interest in personalized medicine and tailored therapies, which is consistent with the healthcare reform in Spain that is aimed at providing more personalized patient care. The adaptation of Montelukast to meet specific patient requirements is becoming increasingly feasible due to Spain's skilled workforce in pharmaceuticals and its robust healthcare infrastructure.

This trend is bolstered by ongoing partnerships between pharmaceutical companies and academic institutions, which are designed to improve the efficacy of Montelukast applications and improve patient outcomes. In general, the Montelukast API market in Spain is characterized by a dynamic environment that is influenced by the interplay of these market drivers and trends.

Source: Primary Research, Secondary Research, MRFR Database, and Analyst Review

## **Spain Montelukast API Market Drivers**

### **Increasing Incidence of Asthma and Allergic Conditions**

The growing prevalence of respiratory disorders, particularly asthma and allergies, serves as a significant driver for the Spain Montelukast Active Pharmaceutical Ingredient (API) Market Industry. Reports indicate that asthma affects approximately 6% of the Spanish population, translating to around 2.5 million individuals.

As highlighted by the Spanish Society of Pneumonology and Thoracic Surgery, there is a rising trend of asthma cases, with an annual increase of about 4%. This surge can be correlated with environmental factors such as air pollution and lifestyle changes among the population, leading to an increasing demand for effective treatments such as Montelukast. Notably, organizations like the Spanish Ministry of Health have been proactive in promoting awareness and facilitating access to asthma treatments, which is likely to further fuel the market for Montelukast API in Spain.

### **Government Initiatives and Healthcare Investments**

Spain's government has been focusing on improving its healthcare system, leading to increased investments that can positively impact the Montelukast API Market Industry. According to recent government reports, Spain's healthcare budget has seen a rise of approximately 6% over the past three years, closely aligning with the strategic aim to enhance chronic disease management.

Initiatives such as the National Asthma Plan, aimed at improving asthma care, are expected to promote the availability of Montelukast API in the market. This enhanced government focus augurs well for the Montelukast API, as better healthcare infrastructure facilitates wider distribution and accessibility of treatments.

### **Growing Awareness of Preventive Healthcare**

There is an increasing awareness among the Spanish populace regarding preventive healthcare, leading to earlier diagnosis and treatment of asthma and allergic conditions. A national survey shows that over 70% of Spaniards acknowledge the importance of early intervention for chronic diseases, suggesting a significant shift towards proactive health management.

Organizations such as the World Health Organization and the Spanish Ministry of Health have played a crucial role in educational campaigns, which have led to a marked increase in prescriptions for asthma medications, including Montelukast. This awareness is driving the need for effective medications, thereby propelling the growth of the Spain Montelukast API Market Industry.

### **Rising Number of Generic Drug Manufacturers**

The entry of generic manufacturers into the Spain Montelukast API Market is fostering competitive pricing and accessibility. Spain is home to several established pharmaceutical companies that have ventured into producing generic versions of Montelukast, which has contributed to a more affordable treatment landscape.

A recent report noted that generic drug penetration in Spain has increased from 40% to nearly 70% in five years, enhancing the market's robustness. Companies like Teva Pharmaceuticals and Sandoz are notably driving this trend, ensuring that a broader segment of the population can access essential medications like Montelukast, consequently escalating market demand.

## **Spain Montelukast API Market Segment Insights**

### **Montelukast API Market Application Insights**

The Spain Montelukast API Market focuses primarily on the Application segment, which plays a critical role in addressing various respiratory and allergic conditions prevalent in the region. The market is fueled by a growing awareness of asthma management and the increasing prevalence of allergic rhinitis, which is particularly common among the Spanish population due to environmental factors and lifestyle.

Asthma treatments remain a major area of focus, given the significant number of patients affected by this chronic condition, necessitating effective management solutions to improve quality of life and reduce hospital visits. Allergic rhinitis is also significant, as it affects a substantial portion of the population, often leading to complications and secondary diseases if not adequately treated.

Bronchospasm and urticaria, though they may receive less attention compared to asthma and allergic rhinitis, still represent important segments within the Montelukast API Market, underscoring the diversity of conditions that require careful management. Effective treatments in these areas can significantly enhance patient comfort and compliance with treatment regimens.

Additionally, the 'others' category encompasses a variety of lesser-known conditions and uses, indicating the versatility of Montelukast as a crucial therapeutic agent across a spectrum of allergic and respiratory issues. The increasing focus on preventive health measures and tailored therapeutic options will drive the future growth of these applications.

This shift represents an opportunity for both healthcare providers and patients to prioritize symptom management and better outcomes in terms of daily activities and overall well-being. As the Spain Montelukast API Market continues to evolve, understanding the nuances of each application will be essential in catering to the specific needs of patients and their healthcare providers in Spain.

The rising demand for more effective treatments and innovations in pharmacology highlights the potential for growth within this segment, advocating for ongoing Research and Development efforts in addressing these prevalent health issues.

Source: Primary Research, Secondary Research, MRFR Database, and Analyst Review

## **Spain Montelukast API Market Key Players and Competitive Insights**

The Spain **[Montelukast Active Pharmaceutical Ingredient (API) Market](../../../reports/montelukast-api-market-7886)** is characterized by a dynamic competitive landscape that is influenced by various factors such as regulatory environments, market demands, and the presence of key players in the pharmaceutical sector. This market primarily revolves around the production and distribution of Montelukast, which is predominantly used to treat asthma and allergic rhinitis.

Competitive insights into this market reveal that companies are continuously striving to enhance their product offerings while navigating challenges such as pricing pressures, patent expirations, and evolving prescribing patterns. Both local manufacturers and multinational corporations shape the competitive environment, all seeking to strengthen their market foothold through innovation, strategic partnerships, and compliance with local regulations.

Teva Pharmaceutical Industries has established a notable presence in the Spain Montelukast API Market, leveraging its extensive experience and well-recognized brand to gain a competitive advantage. The company is known for its robust manufacturing capabilities and a diverse portfolio of generic medications, which includes Montelukast. Teva's strength lies in its ability to deliver high-quality APIs at competitive prices, thanks to its advanced manufacturing processes and economies of scale.

In Spain, Teva has strengthened its market position through strategic distribution agreements and collaborations that allow it to efficiently meet the needs of local healthcare providers. This presence is further enhanced by the company's commitment to maintaining stringent quality control measures and regulatory compliance.

Amgen, while primarily recognized for its biopharmaceuticals and innovative therapies, also plays a significant role in the Spain Montelukast API Market through its involvement in generating effective treatment alternatives. The company has built a strong reputation for exporting quality products while engaging in local partnerships that bolster its market presence.

Amgen’s strengths in Spain are derived from its robust research and development capabilities and its focus on leveraging biotechnology in addressing complex health issues. Although Montelukast might not be the flagship product in their portfolio, Amgen's commitment to enhancing patient outcomes through consultation and innovative therapies has allowed it to maintain a solid foothold.

Additionally, the company actively pursues mergers and acquisitions that can provide synergy to its existing operations, thus enhancing its overall market presence and potential for growth within Spain’s pharmaceutical landscape.

### **Key Companies in the Spain Montelukast API Market Include**

### **Spain Montelukast API Market Industry Developments**

In the Spain Montelukast Active Pharmaceutical Ingredient (API) market, there have been notable developments regarding mergers and acquisitions among key players. For instance, in April 2023, AstraZeneca completed the acquisition of a smaller biopharmaceutical company, enhancing its portfolio in chronic respiratory diseases, potentially impacting Montelukast’s availability in Spain.

Teva Pharmaceutical Industries continues to expand its production capabilities within Spain, focusing on increasing its API output, which may significantly influence market dynamics. Furthermore, Sun Pharmaceutical Industries has recently increased its investment in Research and Development for respiratory treatments, which is set to strengthen its position in the Montelukast segment.

Over the past 2-3 years, market valuation trends have indicated growth, with industry reports showing a steady increase in demand driven by rising respiratory conditions among the population in Spain. In January 2022, Merck Sharp and Dohme announced a partnership to enhance collaborative efforts in respiratory medicine, which is further set to impact Montelukast’s market strategy.

The Spanish government is also pushing for advancements in pharmaceutical production, ensuring a robust regulatory framework that supports the growth of the Montelukast API market.

### **Spain Montelukast API Market Segmentation Insights**

### **Montelukast API Market Application Outlook**

## Market Drivers

### Rising Healthcare Expenditure

The montelukast api market is also influenced by the rising healthcare expenditure in Spain. According to recent reports, healthcare spending in Spain has increased by approximately 5% annually, reflecting a growing commitment to improving health services. This increase in expenditure is likely to enhance the availability of medications, including montelukast, as healthcare providers invest in effective treatment options for respiratory conditions. The montelukast api market stands to benefit from this trend, as patients gain better access to essential medications. Furthermore, the focus on cost-effective treatments may drive the adoption of montelukast, given its established efficacy and safety profile.

### Advancements in Pharmaceutical Research

Advancements in pharmaceutical research are playing a crucial role in shaping the montelukast api market. Ongoing research efforts in Spain are focused on optimizing the formulation and delivery of montelukast, potentially enhancing its therapeutic efficacy. The montelukast api market may benefit from these innovations, as improved formulations could lead to better patient compliance and outcomes. Additionally, collaborations between academic institutions and pharmaceutical companies are fostering a conducive environment for research and development. As new findings emerge, the market could witness the introduction of novel montelukast-based therapies, further expanding its application in respiratory health.

### Growing Awareness of Preventive Healthcare

There is a notable shift towards preventive healthcare in Spain, which is positively impacting the montelukast api market. As patients and healthcare providers increasingly recognize the importance of early intervention in managing respiratory conditions, the demand for preventive treatments like montelukast is likely to rise. Educational campaigns and health programs aimed at promoting awareness of asthma and allergies are contributing to this trend. The montelukast api market may see a surge in prescriptions as more individuals seek proactive measures to manage their health. This growing emphasis on prevention could lead to a more robust market landscape, with montelukast positioned as a key player in respiratory health management.

### Increasing Prevalence of Allergic Conditions

The montelukast api market in Spain is experiencing growth due to the rising prevalence of allergic conditions such as asthma and allergic rhinitis. Recent studies indicate that approximately 10% of the Spanish population suffers from asthma, with a notable increase in cases among children. This trend is likely to drive demand for effective treatments, including montelukast, which is widely prescribed for managing these conditions. The montelukast api market is thus positioned to benefit from this growing patient population, as healthcare providers seek reliable therapeutic options to address the escalating burden of respiratory diseases. Furthermore, the increasing awareness of asthma management among patients and healthcare professionals may further enhance the market's growth prospects.

### Government Initiatives for Respiratory Health

In Spain, government initiatives aimed at improving respiratory health are contributing to the expansion of the montelukast api market. The Spanish Ministry of Health has implemented various programs to promote awareness and management of respiratory diseases, which include funding for research and development of effective treatments. These initiatives are likely to increase the accessibility of montelukast for patients, thereby boosting its demand. Additionally, the montelukast api market may see increased collaboration between public health organizations and pharmaceutical companies, facilitating the introduction of innovative treatment options. As a result, the market could experience a positive impact from these government-led efforts to enhance respiratory health outcomes.

## Future Outlook

The [Montelukast API Market](https://www.marketresearchfuture.com/reports/montelukast-api-market-7886) is projected to grow at a 9.54% CAGR from 2025 to 2035, driven by increasing asthma prevalence and rising healthcare expenditure.

**New opportunities:**

- Development of specialized montelukast formulations for pediatric use.
- Expansion into telehealth services for asthma management.
- Partnerships with pharmaceutical companies for co-marketing initiatives.

By 2035, the montelukast API market is expected to achieve substantial growth and innovation.

## Segment Insights

### By Application: Asthma (Largest) vs. Allergic Rhinitis (Fastest-Growing)

The Spain montelukast api market exhibits a diverse application landscape, with asthma commanding the largest share among the segment values. This condition benefits significantly from montelukast, given its effectiveness in reducing bronchospasm and promoting improved airflow. Following closely is allergic rhinitis, which, while currently smaller in market share, is rapidly gaining attention due to rising awareness and increasing diagnosis rates in the population. 

Growth trends indicate that the demand for montelukast in allergic rhinitis is expanding swiftly, driven by factors such as heightened healthcare access and a growing focus on respiratory health. Ongoing research and development are also propelling innovation in the application of montelukast for various indications, adding momentum to its uptake in the Spain market, particularly for emerging conditions and seasonal allergies.

Asthma (Dominant) vs. Allergic Rhinitis (Emerging)

Asthma remains the dominant application in the Spain montelukast api market, characterized by a well-established therapeutic regimen and strong physician endorsements. Patients benefit from montelukast's ability to mitigate asthma symptoms effectively, which boosts its usage in this segment. On the other hand, allergic rhinitis is emerging as a significant competitor, with increasing prescriptions fueled by growing public awareness and environmental triggers. The rising incidence of allergies, particularly in urban areas, has created a robust market for treatments like montelukast. With healthcare professionals increasingly recognizing allergic rhinitis's impact on quality of life, this segment's growth potential looks promising, positioning allergic rhinitis as a key area for future development and marketing efforts.

## Competitive Benchmarking

The montelukast API market in Spain is characterized by a competitive landscape that is shaped by several key players, each employing distinct strategies to enhance their market presence. The growth drivers in this sector include increasing prevalence of asthma and allergic rhinitis, alongside a rising demand for cost-effective therapeutic options. Companies such as Merck & Co (US), Teva Pharmaceutical Industries (IL), and Mylan N.V. (US) are at the forefront, focusing on innovation and strategic partnerships to bolster their operational capabilities. Merck & Co (US) emphasizes research and development to enhance its product offerings, while Teva Pharmaceutical Industries (IL) is actively pursuing regional expansion to tap into emerging markets. Mylan N.V. (US) appears to be concentrating on supply chain optimization to improve efficiency and reduce costs, collectively shaping a competitive environment that is both dynamic and multifaceted.The business tactics employed by these companies include localizing manufacturing and optimizing supply chains to enhance responsiveness to market demands. The market structure is moderately fragmented, with a mix of established players and emerging competitors. This fragmentation allows for a diverse range of products and pricing strategies, which can be advantageous for consumers but also intensifies competition among key players.

In October  Teva Pharmaceutical Industries (IL) announced a strategic partnership with a local Spanish pharmaceutical firm to enhance its distribution network. This move is likely to improve Teva's market penetration and facilitate quicker access to montelukast APIs across Spain, thereby strengthening its competitive position. The partnership underscores the importance of local collaborations in navigating regulatory landscapes and meeting specific market needs.

In September  Mylan N.V. (US) launched a new formulation of montelukast API aimed at improving patient compliance. This innovation is significant as it addresses the growing demand for more user-friendly medication options, potentially increasing Mylan's market share. The introduction of this formulation reflects a broader trend towards patient-centric approaches in pharmaceutical development, which may redefine competitive dynamics in the market.

In August  Merck & Co (US) expanded its manufacturing capabilities in Spain, investing €50 million in a new facility dedicated to the production of montelukast APIs. This expansion is indicative of Merck's commitment to enhancing its supply chain reliability and meeting the increasing demand for its products. Such investments are crucial in a market where efficiency and capacity can significantly influence competitive advantage.

As of November  current trends in the montelukast API market include a strong emphasis on digitalization, sustainability, and the integration of AI technologies in manufacturing processes. Strategic alliances are increasingly shaping the competitive landscape, allowing companies to leverage shared resources and expertise. Looking ahead, it appears that competitive differentiation will evolve from traditional price-based strategies to a focus on innovation, technological advancements, and robust supply chain management. This shift may ultimately lead to a more sustainable and resilient market environment.

## Recent News & Developments

In the Spain Montelukast Active Pharmaceutical Ingredient (API) market, there have been notable developments regarding mergers and acquisitions among key players. For instance, in April 2023, AstraZeneca completed the acquisition of a smaller biopharmaceutical company, enhancing its portfolio in chronic respiratory diseases, potentially impacting Montelukast’s availability in Spain.

Teva Pharmaceutical Industries continues to expand its production capabilities within Spain, focusing on increasing its API output, which may significantly influence market dynamics. Furthermore, Sun Pharmaceutical Industries has recently increased its investment in Research and Development for respiratory treatments, which is set to strengthen its position in the Montelukast segment.

Over the past 2-3 years, market valuation trends have indicated growth, with industry reports showing a steady increase in demand driven by rising respiratory conditions among the population in Spain. In January 2022, Merck Sharp and Dohme announced a partnership to enhance collaborative efforts in respiratory medicine, which is further set to impact Montelukast’s market strategy.

The Spanish government is also pushing for advancements in pharmaceutical production, ensuring a robust regulatory framework that supports the growth of the Montelukast API market.

## Report Scope

| MARKET SIZE 2024 | 20.2(USD Million) |
| --- | --- |
| MARKET SIZE 2025 | 22.13(USD Million) |
| MARKET SIZE 2035 | 55.04(USD Million) |
| COMPOUND ANNUAL GROWTH RATE (CAGR) | 9.54% (2025 - 2035) |
| REPORT COVERAGE | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
| BASE YEAR | 2024 |
| Market Forecast Period | 2025 - 2035 |
| Historical Data | 2019 - 2024 |
| Market Forecast Units | USD Million |
| Key Companies Profiled | Merck & Co (US), Teva Pharmaceutical Industries (IL), Mylan N.V. (US), Sandoz (CH), Aurobindo Pharma (IN), Cipla (IN), Hikma Pharmaceuticals (GB), Zydus Cadila (IN) |
| Segments Covered | Application |
| Key Market Opportunities | Growing demand for montelukast API driven by increasing respiratory disorders and regulatory support for generic formulations. |
| Key Market Dynamics | Regulatory changes and competitive pressures shape the montelukast API market dynamics in Spain. |
| Countries Covered | Spain |

## Frequently Asked Questions

**Q: What was the market valuation of montelukast API in Spain in 2024?**
A: The market valuation of montelukast API in Spain was $20.2 Million in 2024.

**Q: What is the projected market valuation for montelukast API in Spain by 2035?**
A: The projected market valuation for montelukast API in Spain is $55.04 Million by 2035.

**Q: What is the expected CAGR for the montelukast API market in Spain during 2025 - 2035?**
A: The expected CAGR for the montelukast API market in Spain during 2025 - 2035 is 9.54%.

**Q: Which companies are the key players in the montelukast API market in Spain?**
A: Key players in the montelukast API market in Spain include Merck & Co, Teva Pharmaceutical Industries, Mylan N.V., Sandoz, Aurobindo Pharma, Cipla, Hikma Pharmaceuticals, and Zydus Cadila.

**Q: What application segment had the highest valuation in the montelukast API market in 2024?**
A: The asthma application segment had the highest valuation in the montelukast API market, reaching $8.0 Million in 2024.

**Q: What is the projected growth for the allergic rhinitis segment in the montelukast API market by 2035?**
A: The allergic rhinitis segment is projected to grow from $5.0 Million in 2024 to a higher valuation by 2035.

**Q: How does the bronchospasm segment perform in the montelukast API market?**
A: The bronchospasm segment was valued at $3.0 Million in 2024 and is expected to see growth during the forecast period.

**Q: What is the valuation range for the urticaria segment in the montelukast API market?**
A: The urticaria segment had a valuation range of $2.0 Million to $5.0 Million in 2024.

**Q: What does the 'others' segment represent in the montelukast API market?**
A: The 'others' segment represented a valuation range of $2.2 Million to $5.04 Million in 2024.

**Q: How do the key players influence the montelukast API market in Spain?**
A: The key players, such as Merck & Co and Teva Pharmaceutical Industries, likely influence the montelukast API market through innovation and competitive pricing.


---

*This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/spain-montelukast-api-market-53099*